Sanofi (SNY) Q4 FY25 earnings call

Sanofi delivered strong Q4 and full-year 2025 results, driven by new product launches and Dupixent's continued expansion, reinforcing its R&D-driven biopharma strategy. The company completed its share buyback program and reinvested Opella divestment proceeds into strategic M&A and pipeline development, while navigating pipeline setbacks and anticipating profitable growth into the next decade.